Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Prasun Pudasainee"'
Autor:
Gaurav Nepal, Mahika Khurana, Domenica Herrera Bucheli, Siddhartha Bhandari, Utsav Joshi, Riwaj Bhagat, Jessica Holly Rehrig, Prasun Pudasainee, Yow Ka Shing, Juan Fernando Ortiz, Rajeev Ojha, Bikram Prasad Gajurel, Jonathan Quinonez, Samir Ruxmohan, Trevine Albert, Steven Licata, Joel Stien
Publikováno v:
Neurology International, Vol 14, Iss 1, Pp 99-108 (2022)
Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1–2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL
Externí odkaz:
https://doaj.org/article/47ef347b78db4bdc988035daef4bcf49
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
Chronic myelomonocytic leukemia (CMML) is a relatively rare clonal hematologic disorder with features of myelodysplastic syndrome and myeloproliferative disease. Extramedullary leukemic involvement is rarely a presenting feature of CMML. As there are
Externí odkaz:
https://doaj.org/article/a4bd4e21e74b4967bcb6244ec9f18f04
Publikováno v:
Cardiology Research. 13:393-397
Autor:
Pabitra Adhikari, Drashti Antala, Bimatshu Pyakuryal, Ahmed Muhammed, Prasun Pudasainee, Harvey Friedman, Chizoba J Ezepue
Publikováno v:
Cureus.
Autor:
Aswin Ratna Kansakar, Ekta Shrestha, Guillermo Rodriguez Nava, Clio Musurakis, Prasun Pudasainee, Mariam Charkviani, Harvey J. Friedman, Alisha Sharma, Shanmugha Padhamanbhan, Amrit Devkota, Solab Chitrakar, Mina Sous, Rabin Banjade
Publikováno v:
Obesity Medicine
Background Type 2 diabetes (T2D) is the leading non-communicable disease worldwide and is associated with several microvascular and macrovascular complications. Individuals with T2D are more prone to acquiring selected types of infections and are mor
Autor:
Prajwal Dhakal, Prasun Pudasainee, Vijaya Raj Bhatt, Krishna Gundabolu, Venkat Rajasurya, Bimatshu Pyakuryal
Publikováno v:
Clin Lymphoma Myeloma Leuk
Prospective evidence for management of therapy-related acute myeloid leukemia (t-AML) is limited, with evidence extrapolated from major AML trials. Optimal treatment is challenging and needs consideration of patient-specific, disease-specific, and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b95205ff33a45023c0be08b3d6d6d8b
https://europepmc.org/articles/PMC9302428/
https://europepmc.org/articles/PMC9302428/